Press Ganey is introducing three AI-powered solutions for healthcare leaders in safety, human resources, nursing, patient experience and marketing.
Category: Featured
Digital health funding dips: Report
U.S. digital health startups secured $10.1 billion across 497 deals in 2024, slightly below 2023 figures, a Jan. 13 report from Rock Health found.
Adventist names hospital president
Daffodil Baez has been named president of Adventist HealthCare Fort Washington (Md.) Medical Center.
UR Medicine Thompson Health adds New York GI practice
A Canandaigua, N.Y.-based gastroenterology practice has joined UR Medicine Thompson Health, according to a Jan. 13 report from FingerLakes.com.
A long road ahead for alcohol cancer risk conversations: Viewpoint
The alcohol advisory released by Surgeon General Vivek Murthy, MD, is “likely only one in an evolving history of landmark public health documents about the dangers of drinking; it’s a document for the archives as well as the moment,” Rachael Bedard, MD…
3rd person implanted with Elon Musk's Neuralink, more to follow
Elon Musk said a third person has received his Neuralink implant and plans to give it to 20 to 30 more people this year, U.S. News & World Report reported Jan. 13.
Sutter Health, GE ink $1B AI deal
Sacramento, Calif.-based Sutter Health has signed a seven-year partnership with GE HealthCare to bring AI-powered medical technology to its health system.
Sutter-leased medical office building sold for $9.2M
A medical office building in Roseville, Calif., has been acquired by Montecito Medical Real Estate for $9.205 million, according to a Jan. 13 report from the Sacramento Business Journal.
The best healthcare jobs for 2025, per US News
U.S. News & World Report has released its annual ranking of the 100 best jobs, highlighting the best jobs across 17 categories, including healthcare.
AbbVie to write off $3.5B over failed schizophrenia drug
AbbVie will write off $3.5 billion related to its $8.7 billion investment in Cerevel Therapeutics following the failure of the company’s key schizophrenia drug, emraclidine, The Wall Street Journal reported Jan. 10.
